Order Article Reprints

Carmell N, Rominiyi O, Myers KN, McGarrity-Cottrell C, Vanderlinden A, Lad N, Perroux-David E, El-Khamisy SF, Fernando M, Finegan KG, et al. Identification and Validation of ERK5 as a DNA Damage Modulating Drug Target in Glioblastoma. Cancers. 2021; 13(5):944. https://doi.org/10.3390/cancers13050944

Carmell, Natasha, Ola Rominiyi, Katie N. Myers, Connor McGarrity-Cottrell, Aurelie Vanderlinden, Nikita Lad, Eva Perroux-David, Sherif F. El-Khamisy, Malee Fernando, Katherine G. Finegan, and et al. 2021. "Identification and Validation of ERK5 as a DNA Damage Modulating Drug Target in Glioblastoma" Cancers 13, no. 5: 944. https://doi.org/10.3390/cancers13050944

Carmell, N., Rominiyi, O., Myers, K. N., McGarrity-Cottrell, C., Vanderlinden, A., Lad, N., Perroux-David, E., El-Khamisy, S. F., Fernando, M., Finegan, K. G., Brown, S., & Collis, S. J. (2021). Identification and Validation of ERK5 as a DNA Damage Modulating Drug Target in Glioblastoma. Cancers, 13(5), 944. https://doi.org/10.3390/cancers13050944